INTRODUCTION
Lung Cancer is the leading cause of death from cancer for both men and women in the United States and in most parts of the world, with a 5-year survival rate of 15% 1 . Non-small-cell lung cancer (NSCLC) is the most common cause of lung cancer death, accounting for up to 85% of such deaths 2 . Clinical-pathologic staging is the standard prognosis factor for lung cancer used in clinical practice, but does not capture the complexity of the disease so that heterogeneous clinical outcomes within the same stage are commonly seen. Several randomized clinical trials showed that adjuvant chemotherapy improves survival in resected NSCLC [3] [4] [5] [6] [7] The effect of adjuvant chemotherapy on prolonging survival is modest -only 4-15% improvement in 5-year survival, while such treatment is associated with serious adverse effects 6, 8 . Therefore, it is of considerable clinical importance to have a robust and accurate prognostic signature for lung cancer, especially in early stage lung cancer to improve the current clinical decisions on whether an individual lung cancer patient should receive adjuvant chemotherapy or not.
Genome-wide expression profiles have been used to identify gene signatures to classify lung cancer patients with different survival outcomes [9] [10] [11] [12] [13] [14] [15] [16] . However, the requirement of frozen tissues for microarray experiments limits the clinical usage of these gene signatures. Furthermore, prognostic gene signatures for NSCLC developed by different groups show minimal overlap, and are often difficult to reproduce by independent groups [17] [18] . To address the problem of requirement for frozen issues, we designed this study to test the feasibility of developing lung cancer prognosis gene signatures using genome-wide expression profiling of formalin-fixed paraffinembedded (FFPE) samples, which are widely available and provide a valuable rich Author Manuscript Published OnlineFirst on July 8, 2011; DOI: 10.1158/1078-0432.CCR- source for studying the association of molecular changes in cancer and associated clinical outcomes. We derived a prognosis signature for NSCLC from FFPE samples and validated it in several independent studies. To facilitate other researchers to reproduce all results in this study, we have provided a literate programming R package.
MATERIALS AND METHODS
Tissue specimens. The overall study design and the flow chart of the derivation and validation of the robust gene signature are described in Microarray data preprocessing and quality control. Total RNA was processed for analysis on the Affymetrix U133 plus 2.0 arrays according to Affymetrix protocols for first-and second-strand synthesis, biotin labeling and fragmentation. The quality control procedure for microarray data analysis was based on the percentage of present calls calculated by the MAS5 package. We selected arrays with at least 15% of probe sets present; 55 out of 75 arrays passed this quality control criterion and will be used for the analysis. We selected probe sets that are present on all 55 arrays; 1400 genes past this criterion. These 1400 genes were referred as the robust gene set (RGS) since the mRNA expression of these genes are robust to FFPE processing. The 55 samples and the 1400 genes were used to develop gene signatures.
After microarray analysis QC, we used the RMA background correction algorithm 19 to remove non-specific background noise. A robust regression model 20 was fitted to the probe level data, and the fitted expression values for the probes at the 3' end were used to summarize the probe set expression values. Quantile-quantile normalization was used to normalize all the arrays. Consortium microarray raw data 13 was downloaded from the National Cancer Institute's caArray database and preprocessed by RMA background correction and quantile-quantile normalization. All gene-expression values were log-transformed (on a base 2 scale).
Research. Supervised classification using supervised principal component analysis.
Classification was performed using supervised principal component analysis [21] [22] , a widely used classification method in biomedical research [23] [24] [25] [26] . As a supervised classification method, each prediction model was trained in a training dataset and then the performance was tested in an independent test dataset. We used an R package Survival analysis. Overall survival time was calculated from the date of surgery until death or the last follow-up contact. Survival curves were estimated using the productlimit method of and were compared using the log-rank test. The maximum follow-up time for the FFPE patient cohort is less than 7 years, while some patients in the consortium cohort have been followed for up to 17 years. To avoid the extrapolation of the prediction model, the comparison of survival time between predicted groups are truncated at 7 years. The analysis results without truncation can be seen in Supplementary Sweave Report. Univariate and multivariate Cox proportional-hazards analysis 28 were also performed, with survival as the dependent variable.
Research. 
RESULTS
The robust gene set defines two tumor groups. The expression of these 1400 genes divided the 55 patients into two groups based on unsupervised clustering analysis (with euclidean distance and complete linkage for the hierarchical clustering algorithm) (Figure 2) . Interestingly, group 1 has significantly shorter survival time compared to group 2 (Figure 2b, HR=3 Table 3 ). The other clinical characteristics including gender, age and smoking status were not significantly different between the two groups. To explore whether the association between RGS groups and survival is due to the histology difference between two groups, we drew Kaplan-Meier curves by both histology and RGS groups (Supplementary Figure 1) and it shows clearly that RGS can distinguish high and low risk groups within both adenocarcinoma and squamous groups indicating the association of RGS groups and survival is independent of histology groups.
We used gene set enrichment analysis (GSEA) to identify the enriched gene gene sets are summarized in Supplementary Table 4 ; notably, genes enriched in group 1 are also enriched in mouse neural stem cells and embryonic stem cells.
Construct and validate RGS prognosis signatures.
FFPE samples training to testing. The strong associations between RGS groups and survival outcomes motivated us to explore whether RGS expression profile can be used to construct prognosis signature. We randomly divided 55 patients into training (25 samples) and testing (30 samples) sets, and constructed a prediction model using 1400 robust gene expression values in the training set through a supervised principle component approach 21 . Figure 3a shows that the predicted low risk group has significant longer survival time than the predicted high risk group (P=0.013) in the testing set. To test if this association was not random, we randomly split the data into training and testing sets 200 times, repeated the same prediction and testing procedures for each set, and found that the prognosis performance of RGS signature is significantly better than random (P=0.02).
Frozen samples training to testing. We then tested whether this robust gene set can be used to construct prognosis signature in frozen samples. The largest independent public available lung cancer microarray data set is the recently published NCI Director's Consortium for study of lung cancer involving 442 resected adenocarcinomas 13 . From that study, Affymetrix U133A microarray data for the 1012 robust genes were excerpted with 388 less genes than our FFPE data due to the microarray platform difference. We used the same training and testing strategy as in the original analyses of these data the hazard ratio for our RGS signature is 2.89 on the same MSK test set. For the CAN/DF test set, the hazard ratios range from 1.76-2.30 using the published signatures, while the hazard ratio for our RGS signature on the same CAN/DF test set is 2.39. Therefore, the prognosis performance of RGS prognosis is at least as good as other published signatures in the microarray dataset.
The RGS prognosis signature is independent of clinical variables. To test whether RGS is an independent prognosis signature, we fitted a multivariate Cox regression model including RGS risk scores, age, gender, stage, smoking status, adjuvant chemotherapy usage and clinical sites as co-variables for the consortium data set. The RGS risk scores were calculated from the prediction model built from the FFPE samples set. Table 1 shows that the RGS signature is significantly associated with the survival time after adjusting for other clinical variables (HR=1.3, P=0.007).
Pathological stages based on international staging system is the most widely used and important prognosis variable for lung cancer patients 30 , here we tested whether RGS signature can further refine the prognosis within each stage. The RGS prognosis signature from FFPE samples was tested within each stage of the consortium dataset.
The results show clearly that the RGS signature is significantly associated with survival outcome within each stage (Figure 3e to g Figure 3 a,b Figure 5c, HR=2.10, P=0.02, respectively) . Furthermore this signature can also significantly distinguish the high and low risk groups within stage I patients for both datasets (Figure 5b 5d) Figure 4 a-d) .
To understand the potential biological relevance of these 59 genes significantly associated with survival in the FFPE and consortium data sets, we used Ingenuity Pathway Analysis (IPA) to explore which known regulatory networks are enriched in this 59-gene set. IPA analysis revealed the most significant molecular networks to be cancer, tumor morphology, and respiratory disease. This network (Figure 4c ) includes 14 genes of the 59-gene set and is centered on transcription factors HNF4A, HNF1A, and ONECUT1 (HNF6A). This hepatocellular network has been implicated in hepatocellular carcinoma as determined by in vitro study 32 and molecular interactions in this network are putatively involved in lung cancer survival.
DISCUSSION
In this study, we tested the feasibility of deriving a lung cancer prognosis gene . A recent study demonstrated the feasibility of using DNA-mediated annealing, selection, extension and ligation (DASL) arrays with 6100 preselected genes to profile mRNA expression from hepatocellular carcinoma tissue 41 . No prognosis signature for other types of cancer has been developed using microarray analysis of gene expression from FFPE extracted RNA. In this study, we built a robust gene signature for NSCLC based on microarray analysis of FFPE samples. We claim this is a robust gene signature because it has been validated in 6 independent published datasets including 4 sets from the consortium study and 2 additional studies from DFCI and Duke. We also built a prediction model using the same set of robust genes from frozen samples and validated the model in both frozen and FFPE samples.
Most published gene signatures identified from different studies are usually very different and with little overlap. However, we found that there is significant overlap among the robust genes associated with survival outcomes between the FFPE dataset and the consortium dataset (P=0.008). More impressively, the hazard ratios, indicating the strength of the association of genes expression and survival time, are highly consistent between two independent datasets. Our interpretation for this consistency across studies is that the gene expression variation across studies is a major contribution to signature differences across studies. In this study, we used strict quality steps to exclude genes that were not expressed in our FFPE samples. This allowed for analysis of the remaining genes which had more stable expression patterns and were more robust to environment changes. Validation of our novel 59-gene signature prognostic for NSLC survival in two additional independent datasets further confirmed the robustness of these genes.
By grouping our RGS of 1400 genes by gene expression, we found that the group expression levels correlated with survival. Interestingly, group 1 had a shorter survival and contained an ER negative breast cancer signature. Group 2 had a longer survival and contained an ER positive breast cancer signature. This correlation with ER status and survival has been demonstrated previously in breast cancer and shown to have predictive power for prognosis 29 . In addition to ER status, the RGS groups were separated by the presence of stem cell signatures (embryonic stem cell signature and neural stem cell signature), with group 1 (shorter survival) having two stem cell signatures whereas group 2 (longer survival) did not. The embryonic stem cell signature has previously been shown to be associated with poor prognosis of NSCLC 42 . In addition, in mouse models, a hematopoietic and neural stem cell-like signature in primary tumors has been shown to be a predictor of poor prognosis in 11 types of cancer, including lung 43 . These ER status and stem cell signature data support our RGS expression groupings and their correlation with survival prognosis. Red and black lines represent predicted high-and the low-risk groups, respectively.
Solid and dash lines represent adenocarcinoma and squamous groups, respectively.
• indicates censored samples. • indicates censored samples.
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